Live
GlaxoSmithKline (GSK) Pharmaceuticals Ltd has been investing Rs 1,000 crore in a unit in Karnataka and aims to enhance its global pipeline in areas like respiratory drugs and vaccines in India.
According to the annual report of the company, ” It is investing Rs 1,000 crore in a new state-of-the art pharmaceutical factory in Vemgal, Karnataka. The factory will initially supply a range of solid dose from products. The factory will commence production in 2018 and produce more than 8 billion tablets and 1 billion capsules a year.”
